Regeneron Facing Class Action Lawsuit Over Failed Melanoma Trial

Regeneron Facing Class Action Lawsuit Over Failed Melanoma Trial

2026-07-31 companies

Seattle, Friday, 31 July 2026.
Regeneron faces a class action lawsuit after altering clinical trial protocols for a potential blockbuster cancer drug, concealing slow event rates before the trial ultimately failed and wiped out $11 billion in market value.

Regeneron Facing Class Action Lawsuit Over Failed Melanoma Trial

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities class action lawsuit following disclosures concerning a Phase 3 clinical trial protocol and its ultimate failure, resulting in significant market value loss [2][5]. The lawsuit alleges the company misled investors regarding the study’s flawed statistical assumptions and lack of meaningful differentiation over standard therapies during the class period from August 1, 2025, to May 15, 2026 [2][6]. Investors who acquired Regeneron common stock within this timeframe may be eligible to seek recovery for losses sustained due to alleged securities fraud [7][8].

Trial Protocol Alterations and Market Impact

On April 29, 2026, Regeneron disclosed alterations to the trial protocol, mandating that the primary analysis of progression-free survival include all patients with a minimum of 6 months of follow-up [2][5]. This disclosure caused the stock price to decline 6.2 percent, dropping from $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026 [6][7]. Subsequently, on May 15, 2026, the company announced the trial failed to reach statistical significance for its primary endpoint, leading to a further 9.8 percent decline from $698.25 to $629.68 per share by May 18, 2026 [6][8].

Wider Litigation Wave in July 2026

Beyond Regeneron, litigation firm Hagens Berman Sobol Shapiro LLP has issued multiple securities class action notices targeting other publicly traded companies in July 2026 [1][3]. ADMA Biologics, Inc. (NASDAQ: ADMA) is facing allegations of artificially inflated stock value through undisclosed related-party transactions and channel stuffing, with a lead plaintiff deadline set for August 10, 2026 [1]. Similarly, Wix.com Ltd. (NASDAQ: WIX) investors have until September 22, 2026, to apply for lead plaintiff status in a lawsuit alleging misleading financial statements regarding AI initiative costs [3].

Primoris Services and Investor Deadlines

Primoris Services Corporation (NYSE: PRIM) is also subject to a securities class action investigating potential misleading statements regarding project management capabilities and renewables business revenues [4]. While Primoris investors are encouraged to contact the firm, no specific court-ordered deadline was provided in the initial notice, indicating an ongoing investigation status [4]. For Regeneron investors, the deadline to ask the Court to be appointed as lead plaintiff is September 14, 2026 [6][8].

Investor Deadlines and Recovery Options

Multiple law firms, including Bleichmar Fonti & Auld LLP, Levi & Korsinsky, LLP, and Robbins LLP, are actively soliciting investors for the Regeneron case [6][7][8]. Representation is typically on a contingency fee basis, meaning shareholders are not responsible for court costs or litigation expenses [6]. Affected shareholders across these cases are urged to verify their eligibility and adhere to the specific deadlines to participate in potential recoveries [1][3].

Sources


Securities Litigation Class Action